Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonsecretory multiple myeloma

R Dreicer, R Alexanian

    American Journal of Hematology
    |December 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Multiple myeloma patients without monoclonal globulins, a rare variant, often present with lower tumor burden. This early detection contributes to a longer median survival compared to typical multiple myeloma cases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.

    The Prostate·2025
    Same author

    Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

    ESMO open·2024
    Same author

    Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.

    Prostate cancer and prostatic diseases·2015
    Same author

    A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.

    European journal of cancer (Oxford, England : 1990)·2014
    Same journal

    High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

    American journal of hematology·2026
    Same journal

    Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

    American journal of hematology·2026
    Same journal

    Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

    American journal of hematology·2026
    Same journal

    Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

    American journal of hematology·2026
    Same journal

    Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

    American journal of hematology·2026
    Same journal

    Comparative Efficacy of Intranasal, Intramuscular, and Intravenous Vitamin B12 Therapy for Hematological Recovery in Vitamin B12 Deficiency Anemia: A Randomized Controlled Trial.

    American journal of hematology·2026
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Medicine

    Background:

    • Multiple myeloma is a plasma cell malignancy.
    • A rare variant lacks detectable monoclonal immunoglobulins.
    • Understanding this subtype is crucial for accurate diagnosis and treatment.

    Purpose of the Study:

    • To describe the clinical features and disease course of multiple myeloma patients without monoclonal globulins.
    • To compare their characteristics with typical multiple myeloma patients.
    • To investigate factors influencing survival in this variant.

    Main Methods:

    • Retrospective analysis of 29 consecutive patients with myeloma lacking monoclonal globulins.
    • Comparison of clinical and laboratory data with a cohort of typical myeloma patients.

    Related Experiment Videos

  • Evaluation of tumor burden and survival duration.

    • Main Results:

    • This variant represented 4.7% of referred multiple myeloma cases over 17 years.
    • Patients exhibited bone marrow plasmacytosis and bone lesions but less frequent anemia and preserved immunoglobulin levels.
    • A low tumor mass was observed in 69% of these patients, versus 24% of typical myeloma patients.
    • Median survival was 39 months, approximately 1 year longer than typical patients.

    Conclusions:

    • Multiple myeloma without monoclonal globulins is a distinct subtype with unique clinical features.
    • Lower tumor burden in this variant may contribute to improved survival outcomes.
    • Further research is warranted to optimize management strategies for this specific patient group.